Meeting
2013 ASCO Annual Meeting
Sixteen years follow-up results of a randomized phase II trial of neoadjuvant FAC compared with CMF in stage III breast cancer.
Authors
Ariel Osvaldo Zwenger
Grupo Oncologico Cooperativo del Sur, Neuquen, Argentina
Ariel Osvaldo Zwenger , Julieta Leone , Carlos Teodoro Vallejo , Juan Eduardo Perez , Alberto Omar Romero , Mario Raul Machiavelli , Luis Romero Acuna , Maria Ester Dominguez , Mario Langui , Hebe Margot Fasce , Bernardo Amadeo Leone , Eduardo Ortiz , Jose Pablo Leone , Julian Iturbe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT00002696
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1073)
DOI
10.1200/jco.2013.31.15_suppl.1073
Abstract #
1073
Poster Bd #
22H
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Effect of renal function (RF) on outcomes in the adjuvant treatment of older women with breast cancer (>65 years): CALGB/CTSU 49907 (CC) ancillary data study.
First Author: Stuart M. Lichtman
Poster
2013 ASCO Annual Meeting
Safety and tolerability of adjuvant dose dense chemotherapy in elderly patients with node-positive early breast cancer.
First Author: Vasilios Karavasilis
Poster
2012 ASCO Annual Meeting
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy (NACT) for early breast cancer: Three-year follow-up data.
First Author: Andreas Schneeweiss
Poster
2023 ASCO Annual Meeting
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.
First Author: Claire Palles